Clinical efficacy: The OPTIMIZE-1 study met its primary endpoint, with a confirmed objective response rate of 42.1% in the Phase 2 cohort. Median duration of response was 12.6 months, progression-free ...
LUND, SE / ACCESS Newswire / May 23, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced the presentation of biomarker data from its OPTIMIZE-1 clinical trial at the 2025 American ...
Delineation of immunotherapeutic predictive versus prognostic transcriptional programs to identify SLC22A5-centric carnitine metabolism-driven resistance to anti-PD-L1 treatment in advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results